KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2025)

Historic Gross Margin for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Q3 2025 value amounting to 93.16%.

  • Rigel Pharmaceuticals' Gross Margin rose 76700.0% to 93.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 93.1%, marking a year-over-year increase of 36700.0%. This contributed to the annual value of 89.6% for FY2024, which is 43200.0% down from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Gross Margin stood at 93.16% for Q3 2025, which was up 76700.0% from 95.57% recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Gross Margin ranged from a high of 99.61% in Q1 2021 and a low of 85.49% during Q3 2024
  • Its 5-year average for Gross Margin is 95.19%, with a median of 96.0% in 2023.
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -100000bps in 2024, then soared by 76700bps in 2025.
  • Rigel Pharmaceuticals' Gross Margin (Quarter) stood at 97.61% in 2021, then rose by 2bps to 99.33% in 2022, then decreased by -10bps to 89.41% in 2023, then rose by 1bps to 89.95% in 2024, then grew by 4bps to 93.16% in 2025.
  • Its Gross Margin was 93.16% in Q3 2025, compared to 95.57% in Q2 2025 and 91.73% in Q1 2025.